- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 33
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes, Nonalcoholic Fatty Liver Disease, Vitamin D Deficiency
- Interventions
- Ergocalciferol, placebo
- Dietary Supplement
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 10 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- placebo, BI1356 low dose, BI1356 high dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Norfolk, Virginia
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- High-dose colesevelam, Low-dose colesevelam
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
- Conditions
- Overweight, Leanness, Adolescent
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 36
- States / cities
- Little Rock, Arkansas • Sacramento, California • Whittier, California + 31 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 10 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Oral semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
- Conditions
- Children and Adolescent With Type 2 Diabetes
- Interventions
- Exenatide Once Weekly, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 16
- States / cities
- Los Angeles, California • New Haven, Connecticut • Iowa City, Iowa + 13 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 12 Years to 15 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Obesity, Type 2 Diabetes Mellitus
- Interventions
- Low Glycemic Load Diet versus Low Fat Diet
- Behavioral
- Lead sponsor
- Nazrat Mirza
- Other
- Eligibility
- 7 Years to 14 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more
- Conditions
- Type 2 Diabetes
- Interventions
- Bromocriptine mesylate
- Drug
- Lead sponsor
- VeroScience
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Miami, Florida + 2 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 21
- States / cities
- Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 12 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 10 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Alogliptin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 7
- States / cities
- Miami, Florida • Pineallas Park, Florida • Louisville, Kentucky + 4 more
- Conditions
- Sedentary Behavior, Affect, Metabolic Disturbance, Anxiety, Cardiac Autonomic Nervous System Function
- Interventions
- SIT+WALK, EX
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 8 Years to 11 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diabetes (DM), Diabetes (Insulin-requiring, Type 1 or Type 2), Diabetes in Children, Diabetes in Adolescence
- Interventions
- MiniMed Fit Payload adhesive components
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 5
- States / cities
- Sacramento, California • Santa Barbara, California • Idaho Falls, Idaho + 2 more
- Conditions
- Type 2 Diabetes
- Interventions
- Video Games, Web and DVD knowledge
- Behavioral
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 10 Years to 12 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Metformin, Insulin, Placebo, Linagliptin, Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more
- Conditions
- Obesity, Type 2 Diabetes
- Interventions
- Reach-Out Program, nutritional and exercise program, Reach-In Program, standard of care
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 9 Years to 65 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Toledo, Ohio + 2 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Insulin detemir, Insulin NPH, Diet/exercise
- Drug · Behavioral
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- Atorvastatin 20 mg daily for 3 months
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Gainesville, Florida